News Release

Dr. Yuh visited Nanjing iDatastat, the CRO for APL-1202’s China phase II trial

Between September 20-22, 2014, Dr. Lianng Yuh, a consultant retained by Asieris Pharmaceuticals, visited Nanjing iDatastat Co., Ltd., who is providing the service of data management and biostatistics for APL-1202’s China phase II clinical trial. The parent company of iDatastat, R&G Pharma Studies Co., Ltd., is providing the service of clinical trial management for APL-1202’s China phase II clinical trial.

Dr. Yuh is an internationally recognized expert in clinical data management and biostatistics. He formerly served as a senior director and executive director of the data management and biostatistics departments at Pfizer and AstraZeneca, respectively, and later served as a vice president at Endo Pharmaceuticals, a public US company. Under the guidance of Dr. Yuh, Asieris Pharmaceuticals plans to bring the data quality of APL-1202’s phase II clinical trial in China to the international standard to support the global development of APL-1202.